Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials

References

• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26 Suppl 6:1–158.
   PubMed Web of Science ®Google Scholar
• Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308.
   PubMed Web of Science ®Google Scholar
• Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11(8):673–683.
   PubMed Web of Science ®Google Scholar
• Astermark J, Hermans C, Ezzalfani M, et al. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires. Haemophilia. 2022;28(1):18–26.
   PubMed Web of Science ®Google Scholar
• Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016;22(4):e267–74.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Alprolix® Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf. Accessed July 18, 2022.
   Google Scholar
• Mancuso ME, Mannucci PM. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias. Drug Des Devel Ther. 2014;8:365–371.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Refixia Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf. Accessed July 18, 2022.
   Google Scholar
• Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006;13(6):399–409.
   PubMed Web of Science ®Google Scholar
• Mann DM, Stafford KA, Poon MC, Matino D, Stafford DW. The Function of extravascular coagulation factor IX in haemostasis. Haemophilia. 2021;27(3):332–339.
   PubMed Web of Science ®Google Scholar
• Hart DP, Matino D, Astermark J, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022;13:20406207221085202.
   Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–2323.
   PubMed Web of Science ®Google Scholar
• Iorio A, Fischer K, Blanchette V, et al. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017;117(6):1023–1030.
   PubMed Web of Science ®Google Scholar
• Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. Eur J Clin Pharmacol. 2021;77(8):1193–1200.
   PubMed Web of Science ®Google Scholar
• Marchesini E, Morfini M, Valentino L. Recent Advances in the Treatment of Hemophilia: a Review. Biologics. 2021;15:221–235.
   PubMed Web of Science ®Google Scholar
• Li N, Sawyer EK, Maruszczyk K, et al. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. J Med Econ. 2021;24(1):363–372.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submission to NICE. Available from: http://nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSD-FINAL.pdf. Accessed July 18, 2022.
   Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880–3886.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617.
   PubMed Web of Science ®Google Scholar
• Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313–2324.
   PubMed Web of Science ®Google Scholar
• Escuriola Ettingshausen C, Hegemann I, Simpson ML, et al. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: a randomized trial. Res Pract Thromb Haemost. 2019;3(2):268–276.
   PubMed Web of Science ®Google Scholar
• Batt K, Gao W, Ayyagari R, et al. Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A. J Blood Med. 2019;10:147–159.
   PubMed Web of Science ®Google Scholar
• Bonanad S, Núñez R, Poveda JL, et al. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A. Adv Ther. 2021;38(9):4872–4884.
   PubMed Web of Science ®Google Scholar
• Hakimi Z, Santagostino E, Postma MJ, Nazir J. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: comparative Efficacy Using a Matching Adjusted Indirect Comparison. Adv Ther. 2021;38(2):1263–1274.
   PubMed Web of Science ®Google Scholar
• Klamroth R, Wojciechowski P, Aballéa S, et al. Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with hemophilia A without inhibitors: matching-adjusted indirect comparison of A-LONG and HAVEN Trials. J Blood Med. 2021;12:115–122.
   PubMed Web of Science ®Google Scholar
• Pocoski J, Li N, Ayyagari R, et al. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. J Blood Med. 2016;7:129–137.
   PubMed Web of Science ®Google Scholar
• Vashi P, Batt K, Klamroth R, et al. Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A. J Blood Med. 2021;12:935–943.
   PubMed Web of Science ®Google Scholar
• Astermark J, Wojciechowski P, Aballéa S, Hakimi Z, Nazir J, Klamroth R. Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials. J Blood Med. 2021;12:613–621.
   PubMed Web of Science ®Google Scholar